Skip to Main Content
DownloadHi-Res Photo

Mario Strazzabosco, MD, PhD

Professor of Medicine; Clinical Program Leader, Liver Cancer Program; Deputy Director, Yale Liver Center

Contact Information

Mario Strazzabosco, MD, PhD

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Extensive Research Description

The main focus of my laboratory is the pathophysiology and therapy of diseases of the biliary tree (also called cholangiopathies). This is a large group of chronic liver diseases, congenital or acquired, that causes significant morbility and mortality in both the adult and pediatric population. The pathogenesis of biliary tree diseases is still elusive and, contrary to other areas of hepatology, effective treatment is still lacking. Liver transplantation remains the only treatment available for cases progressing to end-stage liver disease. On the other hand, many complications of liver transplantation involve the biliary tree, and biliary cells are intimately involved in liver repair and regeneration. Therefore, the basic scientific interest of the lab nicely complements the clinical interest of the group as it translates into the practice of transplant Hepatology.

Pathophysiology of cholangiopathies.
Previous work from my laboratory has contributed to the understanding of the normal physiology of biliary cells and to the identification of prototypic mechanisms for biliary damage for which a model human cholangiopathy exists (Fig. 1). Among them, the lab is now addressing the pathophysiology and treatment of Cystic Fibrosis cholangiopathy, polycystic liver disease and Alagille syndrome.

Cystic Fibrosis (CF) that alters the ability of the biliary epithelium to secrete Cl - through CFTR, and may leads to sclerosing cholangitis and biliary cirrhosis. We have shown that CFTR loss of function affects bicarbonate transport in biliary duct cells, which in certain circumstances this block can be overcome by purinergic signaling, by aminoglicoside antibiotics and by sulphonylureas. More recent on-going work focuses: a) on the effects of ursodeoxycholic acid (UDCA) on biliary epithelia from CF mice models, and b) the use of cell transplantation strategies to treat genetic diseases of the biliary tree.

Polycystic diseasesof the liver (PLD) are a group of extremely interesting developmental genetic cholangiopathies. In these diseases altered function of ciliary proteins causes dramatic changes in cholangiocyte biology, from altered development resulting in "ductal plate malformations, to altered secretory response to sheer stress, to hyperproliferation, and stimulation of excessive portal fibrogenesis. We have described an increased expression of angiogenic factors in the biliary and cystic epithelium of patients with ADPKD and with Caroli Disease (Fig.2). Angiopoietin-1 and VEGF overexpression may have an autocrine stimulatory effect on cystic cholangiocyte growth. In collaboration with Dr. Somlo and the Yale ADPKD Center and thanks to a novel technique enabling the propagation of primary cholangiocyte cultures from wild-type and PLD transgenic mice, we are planning to explore the intracellular signaling pathways involved in autocrine angiogenic signaling in PLD cystic epithelium and to evaluate the potential inhibitory effect of VEGF signaling blockade on cyst growth in vivo using ADPKD mice.

Alagille Syndrome, a developmental disease of the biliary tree caused by an altered Jaggeded-1/Notch-2 signaling. The patient with Alagille syndrome has severe ductopenia, is jaundiced, and is severely itching, but rarely develops terminal liver diseases and liver fibrosis is negligible. Studies are ongoing to clarify the role of Notch in liver repair and development. In Alagille syndrome there is important cholestasis in the absence of ductular reaction and with an accumulation of intermediate hepatocytes, our hypothesis is that Notch signaling is needed for progenitor cell progression to a biliary phenotype.

Another interest of my group is to understand the role of "activated" biliary cells and liver progenitor cells in liver repair mechanisms. The hypothesis is that, although both mature hepatocytes and biliary cells are able of substantial proliferation, this is restricted to experimental conditions and to rare human conditions, while in most cases of chronic liver diseases, liver repair requires the activation of a population of liver "progenitor cells" closely related to the epithelial cells of the terminal cholangioles. Specific hystochemical markers and a rigorous morphometric approach progenitor cells reaction are used to study with in a number of prototypic diseases.

Finally, the group is interested on hepatocellular carcinoma (HCC) therapy. HCC is one of the most frequent malignant neoplasms worldwide and a leading cause of mortality in the western cirrhotic population. HCC is also an important indication for liver transplantation. Many questions are still open concerning the optimal treatment of HCC. We are studying a prospectively followed up cohort of cirrhotic patients with incident HCC treated according to the BCLC staging system. Studies are planned to implement strategies to reduce recurrence in this population.

Digestive diseases; Cholangiopathies; Pathophysiology of Cholangiopathies

Coauthors

Research Interests

Cystic Fibrosis; Liver Neoplasms

Selected Publications

  • Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology.Strazzabosco M, Cortesi PA, Conti S, Okolicsanyi S, Rota M, Ciaccio A, Cozzolino P, Fornari C, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Zavaglia C, Perricone G, Munari LM, Mantovani LG, Belli LS. Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology. Liver International : Official Journal Of The International Association For The Study Of The Liver 2020, 40: 60-73. PMID: 31654608, DOI: 10.1111/liv.14285.
  • Liver Matrix in Benign and Malignant Biliary Tract Disease.Fabris L, Cadamuro M, Cagnin S, Strazzabosco M, Gores GJ. Liver Matrix in Benign and Malignant Biliary Tract Disease. Seminars In Liver Disease 2020, 40: 282-297. PMID: 32162285, DOI: 10.1055/s-0040-1705109.
  • The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases.Cadamuro M, Girardi N, Gores GJ, Strazzabosco M, Fabris L. The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases. Frontiers In Medicine 2020, 7: 115. PMID: 32373615, PMCID: PMC7186419, DOI: 10.3389/fmed.2020.00115.
  • Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers 2020, 12 PMID: 32486355, PMCID: PMC7352281, DOI: 10.3390/cancers12061422.
  • The Tumor Microenvironment in Cholangiocarcinoma Progression.Fabris L, Sato K, Alpini G, Strazzabosco M. The Tumor Microenvironment in Cholangiocarcinoma Progression. Hepatology (Baltimore, Md.) 2021, 73 Suppl 1: 75-85. PMID: 32500550, PMCID: PMC7714713, DOI: 10.1002/hep.31410.
  • Animal models for cystic fibrosis liver disease (CFLD).Fiorotto R, Amenduni M, Mariotti V, Cadamuro M, Fabris L, Spirli C, Strazzabosco M. Animal models for cystic fibrosis liver disease (CFLD). Biochimica Et Biophysica Acta. Molecular Basis Of Disease 2019, 1865: 965-969. PMID: 30071276, PMCID: PMC6474816, DOI: 10.1016/j.bbadis.2018.07.026.
  • Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wang XW, Zhu AX. Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. Hepatology (Baltimore, Md.) 2019, 69: 1803-1815. PMID: 30251463, PMCID: PMC6433548, DOI: 10.1002/hep.30289.
  • Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M. Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases. Biochimica Et Biophysica Acta. Molecular Basis Of Disease 2019, 1865: 920-928. PMID: 30264693, PMCID: PMC6658095, DOI: 10.1016/j.bbadis.2018.08.038.
  • Animal models of cholestasis: An update on inflammatory cholangiopathies.Mariotti V, Cadamuro M, Spirli C, Fiorotto R, Strazzabosco M, Fabris L. Animal models of cholestasis: An update on inflammatory cholangiopathies. Biochimica Et Biophysica Acta. Molecular Basis Of Disease 2019, 1865: 954-964. PMID: 30398152, DOI: 10.1016/j.bbadis.2018.07.025.
  • Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.Ippolito D, Querques G, Pecorelli A, Talei Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Journal Of Computer Assisted Tomography 2019, 43: 206-213. PMID: 30407241, DOI: 10.1097/RCT.0000000000000807.
  • Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. Journal Of Hepatology 2019, 70: 700-709. PMID: 30553841, DOI: 10.1016/j.jhep.2018.12.004.
  • Cholangiocyte pathobiology.Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Cholangiocyte pathobiology. Nature Reviews. Gastroenterology & Hepatology 2019, 16: 269-281. PMID: 30850822, PMCID: PMC6563606, DOI: 10.1038/s41575-019-0125-y.
  • The tumour microenvironment and immune milieu of cholangiocarcinoma.Fabris L, Perugorria MJ, Mertens J, Björkström NK, Cramer T, Lleo A, Solinas A, Sänger H, Lukacs-Kornek V, Moncsek A, Siebenhüner A, Strazzabosco M. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver International : Official Journal Of The International Association For The Study Of The Liver 2019, 39 Suppl 1: 63-78. PMID: 30907492, DOI: 10.1111/liv.14098.
  • Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota.Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cellular And Molecular Gastroenterology And Hepatology 2019, 8: 197-207. PMID: 31075352, PMCID: PMC6664222, DOI: 10.1016/j.jcmgh.2019.04.013.
  • Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.Fabris L, Fiorotto R, Spirli C, Cadamuro M, Mariotti V, Perugorria MJ, Banales JM, Strazzabosco M. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nature Reviews. Gastroenterology & Hepatology 2019, 16: 497-511. PMID: 31165788, PMCID: PMC6661007, DOI: 10.1038/s41575-019-0156-4.
  • Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma.Kokabi N, Nezami N, Xing M, Ludwig JM, Strazzabosco M, Kim HS. Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma. Journal Of Comparative Effectiveness Research 2019, 8: 993-1002. PMID: 31512955, DOI: 10.2217/cer-2019-0076.
  • The challenges of primary biliary cholangitis: What is new and what needs to be done.Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. Journal Of Autoimmunity 2019, 105: 102328. PMID: 31548157, DOI: 10.1016/j.jaut.2019.102328.
  • Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium.Strazzabosco M, Fiorotto R, Cadamuro M, Spirli C, Mariotti V, Kaffe E, Scirpo R, Fabris L. Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium. Biochimica Et Biophysica Acta. Molecular Basis Of Disease 2018, 1864: 1374-1379. PMID: 28754453, PMCID: PMC5785585, DOI: 10.1016/j.bbadis.2017.07.023.
  • The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochimica Et Biophysica Acta. Molecular Basis Of Disease 2018, 1864: 1435-1443. PMID: 28757170, PMCID: PMC6386155, DOI: 10.1016/j.bbadis.2017.07.028.
  • The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities.Cortesi PA, Belli LS, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani LG, Strazzabosco M. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.
  • Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy.Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M. Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. Hepatology (Baltimore, Md.) 2018, 67: 972-988. PMID: 28836688, PMCID: PMC5783790, DOI: 10.1002/hep.29400.
  • β-Catenin and interleukin-1β-dependent chemokine (C-X-C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis.Kaffe E, Fiorotto R, Pellegrino F, Mariotti V, Amenduni M, Cadamuro M, Fabris L, Strazzabosco M, Spirli C. β-Catenin and interleukin-1β-dependent chemokine (C-X-C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis. Hepatology (Baltimore, Md.) 2018, 67: 1903-1919. PMID: 29140564, PMCID: PMC5906178, DOI: 10.1002/hep.29652.
  • Animal models of biliary injury and altered bile acid metabolism.Mariotti V, Strazzabosco M, Fabris L, Calvisi DF. Animal models of biliary injury and altered bile acid metabolism. Biochimica Et Biophysica Acta. Molecular Basis Of Disease 2018, 1864: 1254-1261. PMID: 28709963, PMCID: PMC5764833, DOI: 10.1016/j.bbadis.2017.06.027.
  • Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. Gene Expression 2018, 18: 31-50. PMID: 29070148, PMCID: PMC5860940, DOI: 10.3727/105221617X15088670121925.
  • Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine.Carbone M, Cristoferi L, Cortesi PA, Rota M, Ciaccio A, Okolicsanyi S, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Belli LS, Munari LM, Mantovani L, Strazzabosco M. Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. Biochimica Et Biophysica Acta. Molecular Basis Of Disease 2018, 1864: 1415-1422. PMID: 28844954, DOI: 10.1016/j.bbadis.2017.08.025.
  • Animal models of cholangiocarcinoma: What they teach us about the human disease.Cadamuro M, Brivio S, Stecca T, Kaffe E, Mariotti V, Milani C, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. Animal models of cholangiocarcinoma: What they teach us about the human disease. Clinics And Research In Hepatology And Gastroenterology 2018, 42: 403-415. PMID: 29753731, DOI: 10.1016/j.clinre.2018.04.008.
  • Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? Liver International : Official Journal Of The International Association For The Study Of The Liver 2018, 38: 2190-2198. PMID: 29900654, PMCID: PMC6282782, DOI: 10.1111/liv.13901.
  • Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Gonzales EM, Charco R, Zieniewicz K, De Carlis L, Duvoux C. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. Journal Of Hepatology 2018, 69: 810-817. PMID: 29940268, DOI: 10.1016/j.jhep.2018.06.010.
  • Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions.Ippolito D, Querques G, Okolicsanyi S, Talei Franzesi C, Pecorelli A, Lombardi S, Orsini E, Strazzabosco M, Sironi S. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions. European Journal Of Radiology 2018, 106: 62-68. PMID: 30150052, DOI: 10.1016/j.ejrad.2018.07.012.
  • Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/β Catenin Signalling Activation.Riva G, Cilibrasi C, Bazzoni R, Cadamuro M, Negroni C, Butta V, Strazzabosco M, Dalprà L, Lavitrano M, Bentivegna A. Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/β Catenin Signalling Activation. Genes 2018, 9 PMID: 30373123, PMCID: PMC6267016, DOI: 10.3390/genes9110522.
  • Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies.Cannito S, Milani C, Cappon A, Parola M, Strazzabosco M, Cadamuro M. Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies. International Journal Of Molecular Sciences 2018, 19 PMID: 30518128, PMCID: PMC6321547, DOI: 10.3390/ijms19123875.
  • Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway.Cilibrasi C, Riva G, Romano G, Cadamuro M, Bazzoni R, Butta V, Paoletta L, Dalprà L, Strazzabosco M, Lavitrano M, Giovannoni R, Bentivegna A. Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway. PloS One 2017, 12: e0169854. PMID: 28081224, PMCID: PMC5231344, DOI: 10.1371/journal.pone.0169854.
  • Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma.Cadamuro M, Brivio S, Spirli C, Joplin RE, Strazzabosco M, Fabris L. Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. International Journal Of Molecular Sciences 2017, 18 PMID: 28098760, PMCID: PMC5297782, DOI: 10.3390/ijms18010149.
  • Notch signaling and progenitor/ductular reaction in steatohepatitis.Morell CM, Fiorotto R, Meroni M, Raizner A, Torsello B, Cadamuro M, Spagnuolo G, Kaffe E, Sutti S, Albano E, Strazzabosco M. Notch signaling and progenitor/ductular reaction in steatohepatitis. PloS One 2017, 12: e0187384. PMID: 29140985, PMCID: PMC5687773, DOI: 10.1371/journal.pone.0187384.
  • Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.Ippolito D, Querques G, Okolicsanyi S, Franzesi CT, Strazzabosco M, Sironi S. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. European Journal Of Radiology 2017, 90: 34-41. PMID: 28583645, DOI: 10.1016/j.ejrad.2017.02.027.
  • Value-based care in hepatology.Strazzabosco M, Allen JI, Teisberg EO. Value-based care in hepatology. Hepatology (Baltimore, Md.) 2017, 65: 1749-1755. PMID: 28073146, DOI: 10.1002/hep.29042.
  • Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness.Brivio S, Cadamuro M, Strazzabosco M, Fabris L. Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness. World Journal Of Hepatology 2017, 9: 455-468. PMID: 28396716, PMCID: PMC5368623, DOI: 10.4254/wjh.v9.i9.455.
  • Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.Spirli C, Mariotti V, Villani A, Fabris L, Fiorotto R, Strazzabosco M. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease. Journal Of Hepatology 2017, 66: 571-580. PMID: 27826057, PMCID: PMC5316496, DOI: 10.1016/j.jhep.2016.10.032.
  • ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. Journal Of Hepatology 2017, 67: 585-602. PMID: 28323126, DOI: 10.1016/j.jhep.2017.03.006.
  • Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?Zavaglia C, Okolicsanji S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, Strazzabosco M, Belli LS. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? Journal Of Hepatology 2017, 66: 236-237. PMID: 27592303, DOI: 10.1016/j.jhep.2016.08.016.
  • Emerging concepts in biliary repair and fibrosis.Fabris L, Spirli C, Cadamuro M, Fiorotto R, Strazzabosco M. Emerging concepts in biliary repair and fibrosis. American Journal Of Physiology. Gastrointestinal And Liver Physiology 2017, 313: G102-G116. PMID: 28526690, PMCID: PMC5582882, DOI: 10.1152/ajpgi.00452.2016.
  • Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis. Liver International : Official Journal Of The International Association For The Study Of The Liver 2017, 37: 982-994. PMID: 27943549, DOI: 10.1111/liv.13339.
  • Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the "Reactive" Biliary Epithelial Phenotype.Fabris L, Brivio S, Cadamuro M, Strazzabosco M. Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the "Reactive" Biliary Epithelial Phenotype. Stem Cells International 2016, 2016: 2953727. PMID: 26880950, PMCID: PMC4736590, DOI: 10.1155/2016/2953727.
  • Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal Of Hepatology 2016, 65: 524-31. PMID: 27212241, DOI: 10.1016/j.jhep.2016.05.010.
  • The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.Fiorotto R, Villani A, Kourtidis A, Scirpo R, Amenduni M, Geibel PJ, Cadamuro M, Spirli C, Anastasiadis PZ, Strazzabosco M. The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. Hepatology (Baltimore, Md.) 2016, 64: 2118-2134. PMID: 27629435, PMCID: PMC5115965, DOI: 10.1002/hep.28817.
  • Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Mantovani LG, Cortesi PA, Strazzabosco M. Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. Hepatology (Baltimore, Md.) 2016, 64: 1331-42. PMID: 26926906, DOI: 10.1002/hep.28527.
  • Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Research 2016, 76: 4775-84. PMID: 27328733, PMCID: PMC4987167, DOI: 10.1158/0008-5472.CAN-16-0188.
  • Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis.Locatelli L, Cadamuro M, Spirlì C, Fiorotto R, Lecchi S, Maria Morell C, Popov Y, Scirpo R, De Matteis M, Amenduni M, Pietrobattista A, Torre G, Schuppan D, Fabris L, Strazzabosco M. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology (Baltimore, Md.) 2016, 63: 965-82. PMID: 26645994, PMCID: PMC4764460, DOI: 10.1002/hep.28382.
  • Liver-allocation policies for patients affected by HCC in Europe.De Carlis L, Di Sandro S, Centonze L, Lauterio A, Buscemi V, De Carlis R, Ferla F, Sguinzi R, Okolicsanyi S, Belli L, Strazzabosco M. Liver-allocation policies for patients affected by HCC in Europe. Current Transplantation Reports 2016, 3: 313-318. PMID: 28473952, PMCID: PMC5410888, DOI: 10.1007/s40472-016-0117-6.
  • Cystic Fibrosis-Related Liver Diseases: New Paradigm for Treatment Based on Pathophysiology.Fiorotto R, Strazzabosco M. Cystic Fibrosis-Related Liver Diseases: New Paradigm for Treatment Based on Pathophysiology. Clinical Liver Disease 2016, 8: 113-116. PMID: 31041076, PMCID: PMC6490209, DOI: 10.1002/cld.583.
  • Emerging roles of Notch signaling in liver disease.Geisler F, Strazzabosco M. Emerging roles of Notch signaling in liver disease. Hepatology (Baltimore, Md.) 2015, 61: 382-92. PMID: 24930574, PMCID: PMC4268103, DOI: 10.1002/hep.27268.
  • Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. Journal Of Viral Hepatitis 2015, 22: 175-83. PMID: 25040391, PMCID: PMC4519006, DOI: 10.1111/jvh.12278.
  • Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort.Belli LS, Romagnoli R, Nardi A, Marianelli T, Donato F, Corradini SG, Iemmolo RM, Morelli C, Pasulo L, Rendina M, De Martin E, Ponziani FR, Volpes R, Strazzabosco M, Angelico M. Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. Digestive And Liver Disease : Official Journal Of The Italian Society Of Gastroenterology And The Italian Association For The Study Of The Liver 2015, 47: 689-94. PMID: 26055490, DOI: 10.1016/j.dld.2015.04.006.
  • Stimulation of nuclear receptor peroxisome proliferator-activated receptor-γ limits NF-κB-dependent inflammation in mouse cystic fibrosis biliary epithelium.Scirpo R, Fiorotto R, Villani A, Amenduni M, Spirli C, Strazzabosco M. Stimulation of nuclear receptor peroxisome proliferator-activated receptor-γ limits NF-κB-dependent inflammation in mouse cystic fibrosis biliary epithelium. Hepatology (Baltimore, Md.) 2015, 62: 1551-62. PMID: 26199136, PMCID: PMC4618241, DOI: 10.1002/hep.28000.
  • Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma? Journal Of Clinical Medicine 2015, 4: 2028-41. PMID: 26703747, PMCID: PMC4693158, DOI: 10.3390/jcm4121958.
  • Malignancies in Primary Sclerosing Cholangitis--A Continuing Threat.Bonato G, Cristoferi L, Strazzabosco M, Fabris L. Malignancies in Primary Sclerosing Cholangitis--A Continuing Threat. Digestive Diseases (Basel, Switzerland) 2015, 33 Suppl 2: 140-8. PMID: 26641079, PMCID: PMC4939833, DOI: 10.1159/000440826.
  • Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.Morton SD, Cadamuro M, Brivio S, Vismara M, Stecca T, Massani M, Bassi N, Furlanetto A, Joplin RE, Floreani A, Fabris L, Strazzabosco M. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation. Oncotarget 2015, 6: 26052-64. PMID: 26296968, PMCID: PMC4694885, DOI: 10.18632/oncotarget.4482.
  • Posttranslational regulation of polycystin-2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage.Spirli C, Villani A, Mariotti V, Fabris L, Fiorotto R, Strazzabosco M. Posttranslational regulation of polycystin-2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage. Hepatology (Baltimore, Md.) 2015, 62: 1828-39. PMID: 26313562, PMCID: PMC4681612, DOI: 10.1002/hep.28138.
  • Neural cell adhesion molecule and polysialic acid in ductular reaction: the puzzle is far from completed, but the picture is becoming more clear.Strazzabosco M, Fabris L. Neural cell adhesion molecule and polysialic acid in ductular reaction: the puzzle is far from completed, but the picture is becoming more clear. Hepatology (Baltimore, Md.) 2014, 60: 1469-72. PMID: 24995463, PMCID: PMC4520409, DOI: 10.1002/hep.27291.
  • Characterization of animal models for primary sclerosing cholangitis (PSC).Fickert P, Pollheimer MJ, Beuers U, Lackner C, Hirschfield G, Housset C, Keitel V, Schramm C, Marschall HU, Karlsen TH, Melum E, Kaser A, Eksteen B, Strazzabosco M, Manns M, Trauner M. Characterization of animal models for primary sclerosing cholangitis (PSC). Journal Of Hepatology 2014, 60: 1290-303. PMID: 24560657, PMCID: PMC4517670, DOI: 10.1016/j.jhep.2014.02.006.
  • Notch signaling and new therapeutic options in liver disease.Morell CM, Strazzabosco M. Notch signaling and new therapeutic options in liver disease. Journal Of Hepatology 2014, 60: 885-90. PMID: 24308992, DOI: 10.1016/j.jhep.2013.11.028.
  • A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the liver match study.Angelico M, Nardi A, Romagnoli R, Marianelli T, Corradini SG, Tandoi F, Gavrila C, Salizzoni M, Pinna AD, Cillo U, Gridelli B, De Carlis LG, Colledan M, Gerunda GE, Costa AN, Strazzabosco M. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the liver match study. Digestive And Liver Disease : Official Journal Of The Italian Society Of Gastroenterology And The Italian Association For The Study Of The Liver 2014, 46: 340-7. PMID: 24411484, DOI: 10.1016/j.dld.2013.11.004.
  • Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury.Strazzabosco M, Fabris L, Albano E. Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury. Gut 2014, 63: 1693-4. PMID: 25056656, PMCID: PMC4519840, DOI: 10.1136/gutjnl-2014-307712.
  • Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: the egg of columbus or another illusion?Kim AK, Dziura J, Strazzabosco M. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: the egg of columbus or another illusion? Hepatology (Baltimore, Md.) 2013, 58: 819-21. PMID: 23703812, DOI: 10.1002/hep.26498.
  • Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis.Morell CM, Fiorotto R, Fabris L, Strazzabosco M. Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis. Clinics And Research In Hepatology And Gastroenterology 2013, 37: 447-54. PMID: 23806629, DOI: 10.1016/j.clinre.2013.05.008.
  • Protein kinase A-dependent pSer(675) -β-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis.Spirli C, Locatelli L, Morell CM, Fiorotto R, Morton SD, Cadamuro M, Fabris L, Strazzabosco M. Protein kinase A-dependent pSer(675) -β-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis. Hepatology (Baltimore, Md.) 2013, 58: 1713-23. PMID: 23744610, PMCID: PMC3800498, DOI: 10.1002/hep.26554.
  • Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions.Massani M, Stecca T, Fabris L, Caratozzolo E, Ruffolo C, Furlanetto A, Morton S, Cadamuro M, Strazzabosco M, Bassi N. Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions. Oncology Reports 2013, 30: 1143-8. PMID: 23807641, DOI: 10.3892/or.2013.2568.
  • Vascular biology of the biliary epithelium.Morell CM, Fabris L, Strazzabosco M. Vascular biology of the biliary epithelium. Journal Of Gastroenterology And Hepatology 2013, 28 Suppl 1: 26-32. PMID: 23855292, PMCID: PMC3721432, DOI: 10.1111/jgh.12022.
  • Healthcare costs associated with hepatocellular carcinoma and the value of care.Mantovani LG, Strazzabosco M. Healthcare costs associated with hepatocellular carcinoma and the value of care. Hepatology (Baltimore, Md.) 2013, 58: 1213-4. PMID: 23913793, DOI: 10.1002/hep.26645.
  • EASL recognition awardee 2013: Professor Jesus Prieto.Strazzabosco M. EASL recognition awardee 2013: Professor Jesus Prieto. Journal Of Hepatology 2013, 59: 408-10. PMID: 23764136, DOI: 10.1016/j.jhep.2013.05.012.
  • The balance between Notch/Wnt signaling regulates progenitor cells' commitment during liver repair: mystery solved?Strazzabosco M, Fabris L. The balance between Notch/Wnt signaling regulates progenitor cells' commitment during liver repair: mystery solved? Journal Of Hepatology 2013, 58: 181-3. PMID: 22902547, DOI: 10.1016/j.jhep.2012.08.006.
  • Toward a rational management of very early hepatocellular carcinoma.Strazzabosco M. Toward a rational management of very early hepatocellular carcinoma. Hepatology (Baltimore, Md.) 2013, 57: 1300-2. PMID: 22987787, DOI: 10.1002/hep.26074.
  • Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study.Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, Pinna AD, Avolio AW, Fagiuoli S, Burra P, Strazzabosco M, Costa AN. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. Journal Of Hepatology 2013, 58: 715-23. PMID: 23201239, DOI: 10.1016/j.jhep.2012.11.025.
  • Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.Cadamuro M, Nardo G, Indraccolo S, Dall'olmo L, Sambado L, Moserle L, Franceschet I, Colledan M, Massani M, Stecca T, Bassi N, Morton S, Spirli C, Fiorotto R, Fabris L, Strazzabosco M. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology (Baltimore, Md.) 2013, 58: 1042-53. PMID: 23505219, PMCID: PMC3732815, DOI: 10.1002/hep.26384.
  • Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice.Fiorotto R, Raizner A, Morell CM, Torsello B, Scirpo R, Fabris L, Spirli C, Strazzabosco M. Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice. Journal Of Hepatology 2013, 59: 124-30. PMID: 23500150, PMCID: PMC3777645, DOI: 10.1016/j.jhep.2013.02.025.
  • Vascular endothelial growth factors in progenitor cells mediated liver repair.Spirli C, Strazzabosco M. Vascular endothelial growth factors in progenitor cells mediated liver repair. Hepatobiliary Surgery And Nutrition 2013, 2: 65-7. PMID: 24570918, PMCID: PMC3924655, DOI: 10.3978/j.issn.2304-3881.2012.12.05.
  • Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies.Cadamuro M, Morton SD, Strazzabosco M, Fabris L. Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. Translational Gastrointestinal Cancer 2013, 2: 130-144. PMID: 28989865, PMCID: PMC5627657, DOI: 10.3978/j.issn.2224-4778.2013.04.02.
  • Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.Spirli C, Morell CM, Locatelli L, Okolicsanyi S, Ferrero C, Kim AK, Fabris L, Fiorotto R, Strazzabosco M. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology (Baltimore, Md.) 2012, 56: 2363-74. PMID: 22653837, PMCID: PMC3460040, DOI: 10.1002/hep.25872.
  • Development of the bile ducts: essentials for the clinical hepatologist.Strazzabosco M, Fabris L. Development of the bile ducts: essentials for the clinical hepatologist. Journal Of Hepatology 2012, 56: 1159-1170. PMID: 22245898, PMCID: PMC3328609, DOI: 10.1016/j.jhep.2011.09.022.
  • Notch signaling in hepatocellular carcinoma: guilty in association!Strazzabosco M, Fabris L. Notch signaling in hepatocellular carcinoma: guilty in association! Gastroenterology 2012, 143: 1430-4. PMID: 23099244, PMCID: PMC3583012, DOI: 10.1053/j.gastro.2012.10.025.
  • Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.Spirli C, Locatelli L, Fiorotto R, Morell CM, Fabris L, Pozzan T, Strazzabosco M. Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes. Hepatology (Baltimore, Md.) 2012, 55: 856-68. PMID: 21987453, PMCID: PMC3272110, DOI: 10.1002/hep.24723.
  • Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease.Alvaro D, Bragazzi MC, Benedetti A, Fabris L, Fava G, Invernizzi P, Marzioni M, Nuzzo G, Strazzabosco M, Stroffolini T. Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. Digestive And Liver Disease : Official Journal Of The Italian Society Of Gastroenterology And The Italian Association For The Study Of The Liver 2011, 43: 60-5. PMID: 20580332, DOI: 10.1016/j.dld.2010.05.002.
  • Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching.Angelico M, Cillo U, Fagiuoli S, Gasbarrini A, Gavrila C, Marianelli T, Costa AN, Nardi A, Strazzabosco M, Burra P, Agnes S, Baccarani U, Calise F, Colledan M, Cuomo O, De Carlis L, Donataccio M, Ettorre GM, Gerunda GE, Gridelli B, Lupo L, Mazzaferro V, Pinna A, Risaliti A, Salizzoni M, Tisone G, Valente U, Rossi G, Rossi M, Zamboni F. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Digestive And Liver Disease : Official Journal Of The Italian Society Of Gastroenterology And The Italian Association For The Study Of The Liver 2011, 43: 155-64. PMID: 21185796, DOI: 10.1016/j.dld.2010.11.002.
  • Polycystic liver diseases: congenital disorders of cholangiocyte signaling.Strazzabosco M, Somlo S. Polycystic liver diseases: congenital disorders of cholangiocyte signaling. Gastroenterology 2011, 140: 1855-9, 1859.e1. PMID: 21515270, PMCID: PMC3109236, DOI: 10.1053/j.gastro.2011.04.030.
  • Epithelial-mesenchymal interactions in biliary diseases.Fabris L, Strazzabosco M. Epithelial-mesenchymal interactions in biliary diseases. Seminars In Liver Disease 2011, 31: 11-32. PMID: 21344348, PMCID: PMC3729030, DOI: 10.1055/s-0031-1272832.
  • Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization.Fabris L, Cadamuro M, Moserle L, Dziura J, Cong X, Sambado L, Nardo G, Sonzogni A, Colledan M, Furlanetto A, Bassi N, Massani M, Cillo U, Mescoli C, Indraccolo S, Rugge M, Okolicsanyi L, Strazzabosco M. Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology (Baltimore, Md.) 2011, 54: 890-9. PMID: 21618579, PMCID: PMC3753582, DOI: 10.1002/hep.24466.
  • Systemic therapy in hepatocellular carcinoma.Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clinics In Liver Disease 2011, 15: 423-41, vii-x. PMID: 21689622, PMCID: PMC3758582, DOI: 10.1016/j.cld.2011.03.002.
  • "The city of Hepar": rituals, gastronomy, and politics at the origins of the modern names for the liver.Riva MA, Riva E, Spicci M, Strazzabosco M, Giovannini M, Cesana G. "The city of Hepar": rituals, gastronomy, and politics at the origins of the modern names for the liver. Journal Of Hepatology 2011, 55: 1132-6. PMID: 21718666, PMCID: PMC3747976, DOI: 10.1016/j.jhep.2011.05.011.
  • Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice.Fiorotto R, Scirpo R, Trauner M, Fabris L, Hoque R, Spirli C, Strazzabosco M. Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice. Gastroenterology 2011, 141: 1498-508, 1508.e1-5. PMID: 21712022, PMCID: PMC3186841, DOI: 10.1053/j.gastro.2011.06.052.
  • Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C.Svegliati-Baroni G, Faraci G, Fabris L, Saccomanno S, Cadamuro M, Pierantonelli I, Trozzi L, Bugianesi E, Guido M, Strazzabosco M, Benedetti A, Marchesini G. Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut 2011, 60: 108-15. PMID: 20966027, PMCID: PMC3784835, DOI: 10.1136/gut.2010.219741.
  • Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert P, Trauner M. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology (Baltimore, Md.) 2011, 54: 1303-12. PMID: 22006858, PMCID: PMC3744065, DOI: 10.1002/hep.24537.
  • ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology 2010, 138: 360-371.e7. PMID: 19766642, PMCID: PMC3000794, DOI: 10.1053/j.gastro.2009.09.005.
  • Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C.Hov JR, Lleo A, Selmi C, Woldseth B, Fabris L, Strazzabosco M, Karlsen TH, Invernizzi P. Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. Journal Of Hepatology 2010, 52: 712-7. PMID: 20347497, DOI: 10.1016/j.jhep.2009.11.029.
  • Foxa1 and Foxa2 regulate bile duct development in mice.Strazzabosco M. Foxa1 and Foxa2 regulate bile duct development in mice. Journal Of Hepatology 2010, 52: 765-7. PMID: 20347503, PMCID: PMC2862815, DOI: 10.1016/j.jhep.2009.12.022.
  • Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria.De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, Pinelli D, Nani R, Valsecchi MG, Antolini L, Colledan M, Fagiuoli S, Strazzabosco M. Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transplantation : Official Publication Of The American Association For The Study Of Liver Diseases And The International Liver Transplantation Society 2010, 16: 503-12. PMID: 20373461, DOI: 10.1002/lt.22039.
  • Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M. Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology (Baltimore, Md.) 2010, 51: 1778-88. PMID: 20131403, PMCID: PMC2930014, DOI: 10.1002/hep.23511.
  • Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis.Liu X, Invernizzi P, Lu Y, Kosoy R, Lu Y, Bianchi I, Podda M, Xu C, Xie G, Macciardi F, Selmi C, Lupoli S, Shigeta R, Ransom M, Lleo A, Lee AT, Mason AL, Myers RP, Peltekian KM, Ghent CN, Bernuzzi F, Zuin M, Rosina F, Borghesio E, Floreani A, Lazzari R, Niro G, Andriulli A, Muratori L, Muratori P, Almasio PL, Andreone P, Margotti M, Brunetto M, Coco B, Alvaro D, Bragazzi MC, Marra F, Pisano A, Rigamonti C, Colombo M, Marzioni M, Benedetti A, Fabris L, Strazzabosco M, Portincasa P, Palmieri VO, Tiribelli C, Croce L, Bruno S, Rossi S, Vinci M, Prisco C, Mattalia A, Toniutto P, Picciotto A, Galli A, Ferrari C, Colombo S, Casella G, Morini L, Caporaso N, Colli A, Spinzi G, Montanari R, Gregersen PK, Heathcote EJ, Hirschfield GM, Siminovitch KA, Amos CI, Gershwin ME, Seldin MF. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics 2010, 42: 658-60. PMID: 20639880, PMCID: PMC3150510, DOI: 10.1038/ng.627.
  • Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (Baltimore, Md.) 2009, 49: 1972-81. PMID: 19475687, PMCID: PMC3569724, DOI: 10.1002/hep.22891.
  • Differentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation.Strazzabosco M, Fiorotto R, Melero S, Glaser S, Francis H, Spirli C, Alpini G. Differentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation. Hepatology (Baltimore, Md.) 2009, 50: 244-52. PMID: 19444869, PMCID: PMC2738985, DOI: 10.1002/hep.22926.
  • Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease.Alvaro D, Onori P, Alpini G, Franchitto A, Jefferson DM, Torrice A, Cardinale V, Stefanelli F, Mancino MG, Strazzabosco M, Angelico M, Attili A, Gaudio E. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. The American Journal Of Pathology 2008, 172: 321-32. PMID: 18202196, PMCID: PMC2312356, DOI: 10.2353/ajpath.2008.070293.
  • Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development.Fabris L, Cadamuro M, Libbrecht L, Raynaud P, Spirlì C, Fiorotto R, Okolicsanyi L, Lemaigre F, Strazzabosco M, Roskams T. Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. Hepatology (Baltimore, Md.) 2008, 47: 719-28. PMID: 18157837, DOI: 10.1002/hep.22015.
  • Prognostic prediction in hepatocellular carcinoma: from art to science.Strazzabosco M, Cohen E, Emre S. Prognostic prediction in hepatocellular carcinoma: from art to science. Journal Of Clinical Gastroenterology 2008, 42: 221-3. PMID: 18223506, DOI: 10.1097/MCG.0b013e31815ed0a9.
  • Functional anatomy of normal bile ducts.Strazzabosco M, Fabris L. Functional anatomy of normal bile ducts. Anatomical Record (Hoboken, N.J. : 2007) 2008, 291: 653-60. PMID: 18484611, PMCID: PMC3743051, DOI: 10.1002/ar.20664.
  • Type I autoimmune hepatitis presenting with acute liver failure in the setting of wild mushroom ingestion.Rogart JN, Iyer A, Robert ME, Levy G, Strazzabosco M. Type I autoimmune hepatitis presenting with acute liver failure in the setting of wild mushroom ingestion. Journal Of Clinical Gastroenterology 2008, 42: 662-6. PMID: 18496396, PMCID: PMC3762257, DOI: 10.1097/MCG.0b013e3181595b7c.
  • Incidence and management of colorectal cancer in liver transplant recipients.Nishihori T, Strazzabosco M, Saif MW. Incidence and management of colorectal cancer in liver transplant recipients. Clinical Colorectal Cancer 2008, 7: 260-6. PMID: 18650194, PMCID: PMC3755274, DOI: 10.3816/CCC.2008.n.033.
  • Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews. Gastroenterology & Hepatology 2020, 17: 557-588. PMID: 32606456, PMCID: PMC7447603, DOI: 10.1038/s41575-020-0310-z.
  • Value-based medicine, a compass to guide healthcare decisions in the COVID-19 aftermath.Strazzabosco M. Value-based medicine, a compass to guide healthcare decisions in the COVID-19 aftermath. Liver International : Official Journal Of The International Association For The Study Of The Liver 2020, 40: 2076-2078. PMID: 32677111, DOI: 10.1111/liv.14605.
  • Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.Bertolini A, van de Peppel IP, Bodewes FAJA, Moshage H, Fantin A, Farinati F, Fiorotto R, Jonker JW, Strazzabosco M, Verkade HJ, Peserico G. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Hepatology (Baltimore, Md.) 2020, 72: 1864-1872. PMID: 32702162, PMCID: PMC7404414, DOI: 10.1002/hep.31480.
  • Health related quality of life in chronic liver diseases.Cortesi PA, Conti S, Scalone L, Jaffe A, Ciaccio A, Okolicsanyi S, Rota M, Fabris L, Colledan M, Fagiuoli S, Belli LS, Cesana G, Strazzabosco M, Mantovani LG. Health related quality of life in chronic liver diseases. Liver International : Official Journal Of The International Association For The Study Of The Liver 2020, 40: 2630-2642. PMID: 32851764, DOI: 10.1111/liv.14647.
  • Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. European Radiology 2021, 31: 2737-2746. PMID: 33123796, PMCID: PMC8043967, DOI: 10.1007/s00330-020-07381-9.
  • IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.Stein S, Henze L, Poch T, Carambia A, Krech T, Preti M, Schuran FA, Reich M, Keitel V, Fiorotto R, Strazzabosco M, Fischer L, Li J, Müller LM, Wagner J, Gagliani N, Herkel J, Schwinge D, Schramm C. IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. Journal Of Hepatology 2021, 74: 919-930. PMID: 33197512, DOI: 10.1016/j.jhep.2020.10.035.
  • Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Advances In Cancer Research 2021, 149: 321-387. PMID: 33579427, DOI: 10.1016/bs.acr.2020.10.005.
  • Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma.Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.
  • Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opinion On Investigational Drugs 2021, 30: 377-388. PMID: 33622120, PMCID: PMC8194059, DOI: 10.1080/13543784.2021.1880564.
  • Rare and undiagnosed liver diseases: challenges and opportunities.Fabris L, Strazzabosco M. Rare and undiagnosed liver diseases: challenges and opportunities. Translational Gastroenterology And Hepatology 2021, 6: 18. PMID: 33824922, PMCID: PMC7838528, DOI: 10.21037/tgh-2020-05.
  • Fibrocystic liver disease: novel concepts and translational perspectives.Lasagni A, Cadamuro M, Morana G, Fabris L, Strazzabosco M. Fibrocystic liver disease: novel concepts and translational perspectives. Translational Gastroenterology And Hepatology 2021, 6: 26. PMID: 33824930, PMCID: PMC7838530, DOI: 10.21037/tgh-2020-04.
  • Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee A, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal Of Hepatology 2021, 75: 647-658. PMID: 33991637, PMCID: PMC8285256, DOI: 10.1016/j.jhep.2021.04.050.
  • New insights on the role of vascular endothelial growth factor in biliary pathophysiology.Mariotti V, Fiorotto R, Cadamuro M, Fabris L, Strazzabosco M. New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Reports (Online) 2021, 3: 100251. PMID: 34151244, PMCID: PMC8189933, DOI: 10.1016/j.jhepr.2021.100251.
  • Pathological characteristics of liver sinusoidal thrombosis in COVID-19 patients: A series of 43 cases.Kondo R, Kawaguchi N, McConnell MJ, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Sun Z, Utsumi T, Strazzabosco M, Iwakiri Y. Pathological characteristics of liver sinusoidal thrombosis in COVID-19 patients: A series of 43 cases. Hepatology Research : The Official Journal Of The Japan Society Of Hepatology 2021, 51: 1000-1006. PMID: 34260803, PMCID: PMC8444906, DOI: 10.1111/hepr.13696.
  • The Neglected Role of Bile Duct Epithelial Cells in NASH.Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. The Neglected Role of Bile Duct Epithelial Cells in NASH. Seminars In Liver Disease 2021 PMID: 34794182, DOI: 10.1055/s-0041-1739455.
  • Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging.Gross M, Spektor M, Jaffe A, Kucukkaya AS, Iseke S, Haider SP, Strazzabosco M, Chapiro J, Onofrey JA. Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging. PloS One 2021, 16: e0260630. PMID: 34852007, PMCID: PMC8635384, DOI: 10.1371/journal.pone.0260630.

Clinical Trials

ConditionsStudy Title
Hepatitis; HIV/AIDS; Immune System; Infectious DiseasesScreening In Anticipation of Future Research
Edit Profile